None listed
Conditions
Brief summary
COVID-19 is associated with a high rate of lung infection (pneumonia), and it is uncertain for how long the inflammatory changes of pneumonia remain in the lungs once people have recovered from their symptoms and whether this is associated with adverse long-term outcomes. This study aims to determine if there are persistent areas of inflammation in the lungs in people who have recovered clinically from COVID-19 pneumonia, and also to assess whether there is evidence of increased blood vessel inflammatory activity in these people. As inflammation has an important role in the development and progression of cardiovascular disease, the persistence of inflammation may be a predictor of increased risk for future heart disease. 18FDG-PET/CT is an imaging test which is very sensitive to detection of inflammation.
Interventions
The study is a multi-centred prospective observational study involving a cohort of 30 adults who are at least 30 days and no more than 45 days post COVID-19 pneumonia diagnosis. Recruited patients will have an 18F-FDG PET/CT scan which will be assessed for persistent areas of increased inflammation in their lung tissue and for inflammation of blood vessels, indicated by measuring the amount of FDG seen in the aorta. The scan will be performed no less than 30 and no more than 45 days from the d
The study is a multi-centred prospective observational study involving a cohort of 30 adults who are at least 30 days and no more than 45 days post COVID-19 pneumonia diagnosis. Recruited patients will have an 18F-FDG PET/CT scan which will be assessed for persistent areas of increased inflammation in their lung tissue and for inflammation of blood vessels, indicated by measuring the amount of FDG seen in the aorta. The scan will be performed no less than 30 and no more than 45 days from the date of the COVID-19 diagnosis.
Sponsors
Sir Charles Gairdner Hospital
Eligibility
Sex/Gender
All
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
· Both males and females aged 50 years or greater. · At minimum of 30 days and no more than 45 days post COVID-19 pneumonia diagnosis. · Recovered as defined by nasal or oropharyngeal swab confirmed as negative for SARSCoV- 2 in the recovery phase of their illness. · Evidence of pulmonary infiltrates on chest x-ray or Chest CT (multilobar, interstitial or ground glass opacities) suggestive of pneumonia during index admission. · Able to provide informed consent and undergo study procedures
Exclusion criteria
· Clinically unstable patients considered unsuitable for 18FDG-PET/CT test · COVID-19 status unknown at the time of enrolment. · People with poorly controlled diabetes · People with known immuno-deficiency or active malignancy.
Outcome results
None listed